Literature DB >> 24680928

Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491.

Xingxing Wang1, Fei Jiang1, Juan Mu1, Xianqing Ye1, Lu Si1, Shilong Ning1, Zhong Li2, Yuan Li3.   

Abstract

Hepatocellular carcinoma (HCC) represents the third leading cause of cancer-related mortality worldwide. Current standard practices for treatment of HCC are less than satisfactory because of metastasis and recurrence. In addition to treating acute promyelocytic leukemia (APL), arsenic trioxide (As2O3) also suppresses other solid tumors, such as HCC. However, the effects of As2O3 on the migration/invasion potential of liver cancer cells and the molecular mechanisms underlying in remain unclear. Here we found that As2O3 attenuated the migration/invasion potential of HCC cell lines by blocking matrix metalloproteinases (MMPs) activities and inducing a mesenchymal to epithelial transition (MET). Indeed, As2O3 elevated the expression of microRNA-491 (miR-491) via demethylation. On one hand, as a target miRNA of MMP9, miR-491 decreased the MMP9 expression. On the other hand, miR-491 blocked the activation of nuclear factor κB (NF-κB), which transcriptionally inactivated MMP2 and induced a MET (as determined by the increased expression of E-cadherin and decreased expressions of snail, slug, and vimentin). Knockdown of miR-491 abolished the As2O3-induced MMPs inactivation, MET, and the migration/invasion potential of HCC cell lines. By understanding a novel mechanism how As2O3 inhibits the migration/invasion potential of liver cancer cells, our study may help to identify potential therapeutic targets for liver cancer.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Arsenic trioxide; Epithelial-mesenchymal transition; Hepatocellular carcinoma; Matrix metalloproteinases; MicroRNA-491; Nuclear factor κB

Mesh:

Substances:

Year:  2014        PMID: 24680928     DOI: 10.1016/j.toxlet.2014.03.016

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  21 in total

1.  BRD4 induces cell migration and invasion in HCC cells through MMP-2 and MMP-9 activation mediated by the Sonic hedgehog signaling pathway.

Authors:  Yong-Hui Wang; Xiao-Mei Sui; Ya-Na Sui; Qin-Wei Zhu; Kai Yan; Li-Shan Wang; Fei Wang; Jia-Hua Zhou
Journal:  Oncol Lett       Date:  2015-08-04       Impact factor: 2.967

2.  Anti-angiogenic effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, proliferation and tube formation.

Authors:  Meng-Hang Yang; Ke-Jie Chang; Jin-Cheng Zheng; Hai Huang; Guang-Yuan Sun; Xue-Wei Zhao; Bing Li; Qing-Yu Xiu
Journal:  Oncol Lett       Date:  2017-07-04       Impact factor: 2.967

Review 3.  Targeting E-cadherin expression with small molecules for digestive cancer treatment.

Authors:  Yizuo Song; Miaomiao Ye; Junhan Zhou; Zhiwei Wang; Xueqiong Zhu
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

4.  Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand.

Authors:  Lingyan Wang; Zhihui Min; Xiangdong Wang; Mushuang Hu; Dongli Song; Zhenggang Ren; Yunfeng Cheng; Yanhong Wang
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

5.  Therapeutic Potential of Arsenic Trioxide (ATO) in Treatment of Hepatocellular Carcinoma: Role of Oxidative Stress in ATO-Induced Apoptosis.

Authors:  Erika B Dugo; Clement G Yedjou; Jacqueline J Stevens; Paul B Tchounwou
Journal:  Ann Clin Pathol       Date:  2017-01-04

6.  MiR-135a and MRP1 play pivotal roles in the selective lethality of phenethyl isothiocyanate to malignant glioma cells.

Authors:  Taolan Zhang; Yingying Shao; Tang-Yuan Chu; Hsuan-Shun Huang; Yu-Ligh Liou; Qing Li; Honghao Zhou
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

7.  Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells.

Authors:  Ying Shi; Tong Cao; Hua Huang; Chaoqun Lian; Ying Yang; Zhiwei Wang; Jia Ma; Jun Xia
Journal:  Cell Cycle       Date:  2017-11-20       Impact factor: 4.534

8.  Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer.

Authors:  Kun Tao; Jing Yang; Zhenhua Guo; Yuemei Hu; Haihui Sheng; Hengjun Gao; Hongyu Yu
Journal:  Am J Transl Res       Date:  2014-07-18       Impact factor: 4.060

9.  Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer.

Authors:  Hui Ji; Yuan Li; Fei Jiang; Xingxing Wang; Jianping Zhang; Jian Shen; Xiaojun Yang
Journal:  Cancer Sci       Date:  2014-11-05       Impact factor: 6.716

10.  Therapeutic Potential of Delivering Arsenic Trioxide into HPV-Infected Cervical Cancer Cells Using Liposomal Nanotechnology.

Authors:  Xiaoyan Wang; Dong Li; Lucy Ghali; Ruidong Xia; Leonardo P Munoz; Hemda Garelick; Celia Bell; Xuesong Wen
Journal:  Nanoscale Res Lett       Date:  2016-02-18       Impact factor: 4.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.